Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2022

HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2022, on Tuesday, March 15, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 692343. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 44896, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a data-driven research organization, with headquarters in the United States, that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration.

For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/692638/Champions-Oncology-to-Announce-Third-Quarter-Financial-Results-on-Tuesday-March-15-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.03
+5.55 (2.56%)
AAPL  263.83
+1.59 (0.61%)
AMD  239.22
-1.34 (-0.56%)
BAC  51.78
-0.26 (-0.50%)
GOOG  252.72
-4.30 (-1.67%)
META  732.98
+0.81 (0.11%)
MSFT  514.29
-2.50 (-0.48%)
NVDA  181.60
-1.03 (-0.57%)
ORCL  277.04
-0.14 (-0.05%)
TSLA  446.12
-1.31 (-0.29%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.